Skip to main navigation

Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Financials
Governance
IR Resources
- Email Alerts
- Contact IR

Press Releases

Press Releases

Recent Releases

September 6, 2022

Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

August 15, 2022

Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

August 3, 2022

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Press Releases

Year

May 12, 2022

Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates

May 11, 2022

Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting

May 9, 2022

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

May 5, 2022

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees

May 5, 2022

Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter

May 4, 2022

Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card

April 26, 2022

Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership

April 20, 2022

Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment

April 5, 2022

Athira Files Definitive Proxy Statement and Mails Letter to Shareholders

April 4, 2022

Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 11 - 20 of 81

SIGN UP FOR EMAIL ALERTS

CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Main line: (866) 725-0930
Local number: (425) 620-8501
info@athira.com

© Athira Pharma, Inc. All rights reserved.